<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05795309</url>
  </required_header>
  <id_info>
    <org_study_id>22HH8008</org_study_id>
    <nct_id>NCT05795309</nct_id>
  </id_info>
  <brief_title>Automated Insulin Delivery in Type 1 Diabetes Complicated by Gastroparesis</brief_title>
  <acronym>AIDgastro</acronym>
  <official_title>Automated Insulin Delivery in Type 1 Diabetes Complicated by Gastroparesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a staggered randomised controlled trial that aims to assess the impact of an&#xD;
      automated insulin delivery (AID) system on glucose, gastrointestinal and patient-reported&#xD;
      outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following a run-in period of 2 weeks, participants will be randomised to control or hybrid&#xD;
      automated insulin delivery (AID) using the 780G system and will remain in the intervention&#xD;
      phase of the study for 12 weeks (4-week control, then 4-week AID or Control and finally&#xD;
      4-week AID). The total duration for each participant will be 14 weeks. There are 5 study&#xD;
      visits (combination of face to face or/and remote) and two telephone visits in total.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2023</start_date>
  <completion_date type="Anticipated">April 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Staggered randomised control trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>% time spent in glucose target (3.9-10mmol/L)</measure>
    <time_frame>4 - 8 weeks</time_frame>
    <description>The change in % time in glucose target between baseline and intervention/control</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>% time spent in hypoglycaemia (&lt;3.0mmol/L)</measure>
    <time_frame>4 - 8 weeks</time_frame>
    <description>The change in % time in hypoglycaemia(&lt;3.0mmol/L) between baseline and intervention/control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% time spent in hypoglycaemia (&lt;3.9mmol/L)</measure>
    <time_frame>4 - 8 weeks</time_frame>
    <description>The change in % time in hypoglycaemia (&lt;3.9mmol/L) between baseline and intervention/control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% time spent in hyperglycaemia (&gt;10mmol/L)</measure>
    <time_frame>4 - 8 weeks</time_frame>
    <description>The change in % time in hyperglycaemia (&gt;10mmol/L) between baseline and intervention/control</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Gastroparesis</condition>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Hybrid Automated Insulin Delivery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention is the Medtronic 780G Hybrid Automated Insulin Delivery system</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The control is Standard Care with real-time CGM</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hybrid Automated Insulin Delivery</intervention_name>
    <description>Consists of an insulin pump and real-time continuous glucose monitoring (CGM)</description>
    <arm_group_label>Hybrid Automated Insulin Delivery</arm_group_label>
    <other_name>Medtronic 780G</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 18 years of age or older&#xD;
&#xD;
          -  Type 1 diabetes confirmed on the basis of clinical features&#xD;
&#xD;
          -  Type 1 diabetes for greater than 1 year&#xD;
&#xD;
          -  On an intensified insulin regimen with multiple dose injection or insulin pump for &gt; 3&#xD;
             months&#xD;
&#xD;
          -  HbA1c &gt;7.5% (58mmol/mol) (or %TIR 3.9-10mmol/L &lt;52% for participants already using a&#xD;
             continuous glucose sensor)&#xD;
&#xD;
          -  Gastroparesis Cardinal Symptom Index (GCSI) ≥ 18 or evidence of delayed gastric&#xD;
             emptying on nuclear medicine gastric emptying study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Enrolled in other clinical trials&#xD;
&#xD;
          -  Estimated glomerular filtration rate of ≤30ml/min&#xD;
&#xD;
          -  Pregnant or planning pregnancy&#xD;
&#xD;
          -  Have active malignancy or under investigation for malignancy&#xD;
&#xD;
          -  Severe visual impairment&#xD;
&#xD;
          -  Reduced manual dexterity&#xD;
&#xD;
          -  Use of any automated insulin delivery system&#xD;
&#xD;
          -  Unable to participate due to other factors, as assessed by the Chief Investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nick Oliver</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Monika Reddy, PhD</last_name>
    <phone>+44 (0)20 7594 1796</phone>
    <email>m.reddy@imperial.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nick Oliver, FRCP</last_name>
    <phone>+44 (0)20 7594 1796</phone>
    <email>nick.oliver@imperial.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Imperial College London and Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Monika Reddy</last_name>
      <phone>+44 (0)20 7594 1796</phone>
      <email>m.reddy@imperial.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Nick Oliver</last_name>
      <phone>+44 (0)20 7594 1796</phone>
      <email>nick.oliver@imerial.ac.uk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 21, 2023</study_first_submitted>
  <study_first_submitted_qc>March 21, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2023</study_first_posted>
  <last_update_submitted>March 21, 2023</last_update_submitted>
  <last_update_submitted_qc>March 21, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroparesis</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

